Big exec payouts, lawsuits mark gene therapy company's $3.1 billion merger deal

From Astellas' initial interest to the close of the deal took six months. But talks turned intense — and another suitor emerged — before the deal was struck Dec. 2.

Source: bizjournals.com Health Care:Biotechnology headlines - December 31, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news